COMPOSITION OF TRADITIONAL CHINESE MEDICINE AND USE OF COMPOSITION OF TRADITIONAL CHINESE MEDICINE IN PREPARING MEDICINAL PRODUCT FOR PREVENTING AND/OR TREATING CORONAVIRUS DISEASE 2019 Russian patent published in 2024 - IPC A61K36/537 A61K36/258 A61K31/45 A61K9/28 A61P11/00 A61P31/14 

FIELD: pharmaceutical industry.

SUBSTANCE: invention relates to the use of a composition of traditional Chinese medicine in preparing a medicinal product for prevention and/or treatment of disseminated intravascular coagulation in patients with pneumonia caused by COVID-19 coronavirus. Use of a composition of traditional Chinese medicine in the preparation of a medicinal product for preventing and/or treating a condition of disseminated intravascular coagulation in patients with pneumonia caused by COVID-19 coronavirus, where the traditional Chinese medicine composition consists of 90 g by weight of Salvia miltiorrhiza and Panax notoginseng extract and 9 g by weight of borneol, wherein the Salvia miltiorrhiza and Panax notoginseng extract contains the following components, wherein the weight ratio of each component is as follows: 36 mg/g Danshensu; 11 mg/g salvianolic acid T; 17 mg/g of protocatechuic aldehyde; 6 mg/g salvianolic acid D; 7 mg/g rosmarinic acid; 13 mg/g salvianolic acid B; 9 mg/g salvianolic acid A; 17 mg/g notoginsenoside R1; 24 mg/g ginsenoside Rg1; 3 mg/g ginsenoside Re; 18 mg/g of ginsenoside Rb1; 4 mg/g ginsenoside Rd; 0.3 mg/g dihydrotanshinone I; 0.7 mg/g tanshinone I; 0.6 mg/g cryptotanshinone; 2.7 mg/g tanshinone IIA.

EFFECT: obtained medicinal preparation based on the composition of traditional Chinese medicine is effective for preventing and/or treating a condition of disseminated intravascular coagulation in patients with pneumonia caused by COVID-19 coronavirus.

13 cl, 6 tbl, 32 ex